RACURA ONCOLOGY

## ASX Announcement

# Appendix 3Y
# Change of Director's Interest Notice
# Dr Daniel Tillett

**23 September 2026**

This notice reflects the on-market sale of RAC shares held personally by Dr Tillett and the purchase of RAC shares on-market by Nucleics Pty Ltd, a corporate entity sole owned and controlled by Dr Tillett. Dr Tillett has undertaken this change for personal estate and tax planning purposes.

The sale and purchase transfer process remains ongoing. Once completed, Dr Tillett's total interest in Racura Oncology will remain unchanged on a combined direct and indirect basis.

-ENDS-

RACURA ONCOLOGY

## About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that primarily acts by stabilising G4-DNA and RNA structures, driving potent silencing of c-MYC, a key cancer gene dysregulated in up to 70% of all cancers. (E,E)-bisantrene has shown therapeutic activity in cancer patients and has a well-characterised safety profile. Racura's discoveries have supported composition-of-matter IP filings that, if granted, could provide up to 20 years of patent protection for (E,E)-bisantrene.

Racura is advancing RC220, its proprietary formulation of (E,E)-bisantrene, to address significant unmet need across multiple MYC-driven oncology indications. The Company's clinical programs include the EMILI Phase 3 trial in acute myeloid leukaemia, the HARNESS Phase 1a/b trial in combination with osimertinib for EGFR-mutated non-small cell lung cancer, and the CPACS Phase 1a/b trial in combination with doxorubicin, where Racura aims to deliver both anthracycline cardioprotection and enhanced anticancer activity.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson Cancer Center, Sheba Medical Center, University of North Carolina School of Medicine, University of Wollongong, and the University of Newcastle. Racura is actively exploring partnerships, licence agreements, and potential commercial merger and acquisition opportunities to accelerate global patient access to RC220. Learn more at www.racuraoncology.com.

For questions about this announcement or previous Racura Oncology announcements, please visit our Interactive Announcements page.

Racura encourages our investors to go paperless by registering their email details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

cherie.hartley@irdepartment.com.au

*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

| | |
|---|---|
| **Name of entity** | **Racura Oncology Limited** |
| **ABN** | 61 149 318 749 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | **Daniel Tillett** |
| **Date of last notice** | **28 May 2026** |

**Part 1 - Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or indirect interest** | 1. Direct<br>2. Indirect |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | 2. Nucleics Pty Ltd – Daniel Tillett is sole director and sole shareholder. |
| **Date of change** | 16, 17, 18, 21 & 22 September 2026 |
| **No. of securities held prior to change** | 1. 20,269,351 fully paid ordinary shares<br>1,534,712 options exercisable at $1.45, expiring 29/11/2028<br>3,061,101 options exercisable at $4.25, expiring 29/11/2028<br>432,680 options exercisable at $1.67, expiring 30/6/2029 |
| **Class** | Fully paid ordinary shares |
| **Number acquired** | 1. 4,500<br>2. 80,000 |
| **Number disposed** | 1. 89,500 |

| | |
|---|---|
| **Value/Consideration includes brokerage/gst**<br>Note: If consideration is non-cash, provide details and estimated valuation | $172,166.39 - purchases<br>$179,716.56 - sales |
| **No. of securities held after change** | 1. 20,184,351 fully paid ordinary shares<br>1,534,712 options exercisable at $1.45, expiring 29/11/2028<br>3,061,101 options exercisable at $4.25, expiring 29/11/2028<br>432,680 options exercisable at $1.67, expiring 30/6/2029<br>2. 80,000 fully paid ordinary shares |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | On-market purchases and sales for estate planning and tax planning purposes. |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – +Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | No. |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |

+ See chapter 19 for defined terms.